Rosetta Genomics has published data validating its miRview Lung assay as a means to differentiate between the four main types of lung cancer.
The report appeared online last week in the Journal of Molecular Diagnostics.
The assay is based on the expression levels of eight microRNAs, measured using a quantitative RT-PCR platform.
In the study, the assay was validated on an independent set of 451 samples, more than half of which were pre-operative cytologic samples obtained as fine-needle aspirations or bronchial brushings and washings, Rosetta said.
More than 90 percent of the samples were successfully processed with an overall accuracy of 94 percent — a finding obtained with both pathologic and cytologic samples, which Rosetta said demonstrates the assay's ability to differentiate between squamous cell carcinoma, non-squamous non-small cell lung cancer, carcinoid, and small cell carcinoma.
The publication comes on the heels of the New York State Department of Health's conditional approval of miRview Lung (GWDN 6/26/2012).